NCT Number: NCT00006275
Study of Topical Calcitriol in Children With Psoriasis
OBJECTIVES:
I. Determine the therapeutic efficacy and safety of topical calcitriol in children with psoriasis.
Looking for future studies?
Notify MeKey information
Conditions
Age range
4 year–18 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
About this study
PROTOCOL OUTLINE: Patients apply topical calcitriol in petrolatum on a psoriatic lesion daily. Patients also apply petrolatum without calcitriol to another psoriatic lesion daily.
Patients have both lesions photographed prior to therapy, monthly during therapy, and at the completion of therapy. Lesions are assessed weekly for 1 month and then every 2 weeks while on study. Blood samples are collected every 1 to 2 months and urine samples are collected every 2 weeks while on study.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
Diagnosis of psoriasis At least 2 lesions with area at least 30-50 cm2
--Prior/Concurrent Therapy--
No other concurrent therapy for psoriasis No concurrent calcium supplements greater than 1,000 mg/day No concurrent prednisone or other drugs affecting serum or urine calcium levels
--Patient Characteristics--
Renal: No high blood or urinary calcium levels
Other: Not pregnant Negative pregnancy test Fertile patients must use effective contraception
Treatment and study plan
Sponsors and collaborators
Lead sponsor
National Center for Research Resources (NCRR)
Nih
Collaborators
- Boston University
Registry information
Important dates
- Study start
- 2000
- Study completion
- 2000
- First posted
- Sep 12, 2000
- Registry last updated
- Jun 24, 2005
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
NCT03440736
Body Weight, Diabetes Mellitus
Langenau, Baden-Wurttemberg, Germany
View Trial DetailsDose Reduction of IL17 and IL23 Inhibitors in Psoriasis
NCT04340076
Psoriasis, Psoriasis Vulgaris
Brussels, Belgium
View Trial DetailsUsing Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care
NCT07428954
Acne, Acne Vulgaris
Bilbao, Basque Country, Spain
View Trial DetailsTofacitinib for Immune Skin Conditions in Down Syndrome
NCT04246372
Abnormalities, Multiple, Alopecia
Aurora, Colorado, United States
View Trial Details